Noopur S. Raje

Noopur S. Raje's AcademicInfluence.com Rankings

Noopur S. Raje

Medical

#2353

World Rank

#2772

Historical Rank

Oncology

#138

World Rank

#143

Historical Rank

medical Degrees

Noopur S. Raje

Philosophy

#6854

World Rank

#9964

Historical Rank

Logic

#3952

World Rank

#5187

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Noopur S. Raje's Degrees

Masters Medicine University of Mumbai
Doctorate Internal Medicine University of Mumbai

Why Is Noopur S. Raje Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Noopur S. Raje's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. (2015) (1386)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. (2001) (909)
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. (2000) (902)
Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma (2019) (840)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010) (813)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. (2021) (586)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. (2019) (555)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. (2012) (521)
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. (2001) (440)
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. (2005) (431)
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. (2007) (395)
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. (2009) (347)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. (2014) (339)
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. (2013) (322)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application (2005) (317)
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. (2013) (309)
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. (2015) (293)
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. (2006) (291)
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells (2011) (289)
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. (2018) (263)
NCCN clinical practice guidelines in oncology: multiple myeloma. (2009) (260)
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. (2009) (257)
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. (2008) (248)
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (243)
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma (2015) (242)
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. (2009) (239)
Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study (2017) (230)
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. (2006) (224)
A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma (2007) (219)
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. (2019) (213)
Thalidomide--a revival story. (1999) (211)
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease (2010) (210)
Latest advances and current challenges in the treatment of multiple myeloma (2012) (206)
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. (2009) (203)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (2008) (202)
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. (2009) (202)
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. (2010) (196)
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. (2000) (191)
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo (2009) (189)
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study (2018) (188)
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. (2004) (185)
Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients (2013) (183)
Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. (2007) (182)
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). (2019) (182)
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. (2014) (180)
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. (2005) (177)
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (2017) (170)
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. (2010) (168)
Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma (2011) (167)
A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results (1998) (163)
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells (2007) (162)
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. (2004) (162)
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. (2004) (161)
Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma (2010) (155)
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. (2016) (154)
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. (2019) (154)
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). (2004) (153)
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. (2007) (143)
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. (2007) (143)
Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw (2008) (139)
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. (2018) (132)
Neutralizing B-Cell–Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model (2007) (129)
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. (2003) (126)
A Novel Role for CCL3 (MIP-1α) in Myeloma-induced Bone Disease via Osteocalcin Downregulation and Inhibition of Osteoblast Function (2011) (125)
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. (2011) (123)
Genetic interrogation of circulating multiple myeloma cells at single-cell resolution (2016) (121)
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. (2018) (120)
RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells (1999) (117)
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. (2009) (115)
MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (114)
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells (2007) (112)
PR‐924, a selective inhibitor of the immunoproteasome subunit LMP‐7, blocks multiple myeloma cell growth both in vitro and in vivo (2011) (111)
Thalidomide and lenalidomide: Mechanism-based potential drug combinations (2008) (109)
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition (2010) (108)
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. (2005) (108)
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells (2004) (107)
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. (2019) (107)
Cyclin dependent kinases in cancer (2012) (105)
Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. (2015) (102)
Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin (2014) (100)
Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. (1999) (100)
High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical Properties (2009) (99)
Ascorbic acid inhibits antitumor activity of bortezomib in vivo (2009) (98)
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma (2018) (97)
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? (2019) (95)
Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. (2020) (93)
Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death (2015) (87)
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk‐1: A Potential Therapeutic Strategy for Myeloma Bone Disease (2016) (85)
The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival (2015) (83)
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma (2004) (81)
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. (2011) (80)
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. (2009) (80)
Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. (2010) (79)
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors (2018) (78)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study (2008) (77)
Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. (2000) (77)
Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy (2017) (77)
Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib (2009) (76)
Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. (2018) (75)
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. (2000) (74)
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. (2000) (71)
Thalidomide and immunomodulatory drugs as cancer therapy. (2002) (70)
Immunotherapeutic strategies for the treatment of plasma cell malignancies. (2000) (69)
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. (2011) (68)
Multiple myeloma, version 1.2013. (2013) (68)
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells (2011) (68)
Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy (2018) (68)
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. (2021) (67)
Multiple Myeloma, version 3.2018: Featured updates to the NCCN guidelines (2018) (67)
Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment (1997) (66)
Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease (2014) (66)
Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. (1999) (66)
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations (2015) (65)
Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma. (2010) (65)
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. (2013) (65)
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. (2006) (65)
Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. (1999) (64)
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma (2009) (64)
bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study. (2018) (63)
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway (2005) (63)
A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. (2011) (62)
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. (2016) (61)
Kidney disease associated with plasma cell dyscrasias. (2010) (61)
Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. (2020) (60)
A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. (2019) (59)
A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C‐VAMP) as induction treatment followed by autografting in previously untreated myeloma (1997) (58)
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. (2005) (58)
Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage1 (2000) (57)
Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide (2011) (57)
Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma (2015) (57)
p38 mitogen‐activated protein kinase inhibitor LY2228820 enhances bortezomib‐induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications (2008) (57)
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. (2015) (56)
Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes (2020) (56)
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. (2021) (56)
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. (2007) (55)
Neurological manifestations of Waldenström macroglobulinemia (2008) (55)
Current developments in immunotherapy in the treatment of multiple myeloma (2018) (55)
Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone (1999) (54)
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. (2005) (53)
First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results. (2017) (53)
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma (2019) (53)
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with amyloid deposition: a clinicopathologic case series. (2012) (53)
Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma (2017) (53)
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial (2018) (52)
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen‐activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth (2007) (52)
Management of bone disease in multiple myeloma (2014) (49)
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. (2022) (49)
Isolation and characterization of human multiple myeloma cell enriched populations. (2000) (49)
Case records of the Massachusetts General Hospital. Case 9-2008. A 65-year-old woman with a nonhealing ulcer of the jaw. (2008) (48)
Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy (2019) (48)
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. (2010) (48)
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors (2005) (48)
Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study (2020) (48)
Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs (2013) (48)
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study. (2008) (47)
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial (2016) (47)
Myeloma and Bone Disease (2017) (46)
The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG) (2019) (45)
Novel therapies in the treatment of multiple myeloma. (2009) (45)
Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) (2016) (44)
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma (2020) (44)
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. (2012) (43)
Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy (2013) (43)
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma (2007) (43)
Novel therapeutic targets for multiple myeloma. (2010) (42)
Panobinostat and Multiple Myeloma in 2018 (2018) (40)
Novel Bone-Targeted Strategies in Oncology (2010) (40)
Bone Marker–Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study (2015) (39)
An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. (1996) (39)
Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. (2009) (39)
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing (2018) (39)
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. (2020) (38)
Role of the RANK/RANKL Pathway in Multiple Myeloma (2018) (38)
Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study. (2009) (38)
Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (2019) (38)
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma (2008) (38)
Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue. (1995) (37)
Phase 2 study of tabalumab, a human anti‐B‐cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma (2017) (37)
A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity (2014) (37)
Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study (2019) (36)
Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy (2012) (36)
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs (2005) (35)
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide (2014) (35)
VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). (2014) (34)
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients (2012) (34)
Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study. (2007) (34)
Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma (2021) (34)
MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM) (2013) (33)
In vitro and In vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN 9708 Against Multiple Myeloma Cells (2011) (32)
ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM) (2013) (32)
Successful anti‐CD19 CAR T‐cell therapy in HIV‐infected patients with refractory high‐grade B‐cell lymphoma (2019) (32)
Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib (2008) (32)
Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. (2002) (32)
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia (2021) (32)
Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study. (2007) (31)
Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma (2008) (31)
Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up (2010) (30)
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma (2017) (29)
The implication of compromised renal function at presentation in myeloma (2001) (29)
P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells. (2004) (29)
Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma (2021) (28)
Kinetics of paraprotein clearance after autografting for multiple myeloma. (1995) (27)
Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (2020) (27)
Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma (2018) (27)
Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells. (1999) (27)
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway (2007) (26)
A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia (2019) (26)
Denosumab for the treatment of bone disease in solid tumors and multiple myeloma. (2018) (26)
PI3K/p110 is a novel therapeutic target in multiple myeloma (2011) (26)
Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma. (1997) (26)
Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma (2016) (26)
Myeloma bone disease: pathogenesis and treatment. (2017) (26)
Ixazomib for the treatment of multiple myeloma (2018) (25)
Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma (2014) (25)
Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study. (2018) (24)
Bone Anabolic Agents for the Treatment of Multiple Myeloma (2011) (24)
Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study (2012) (24)
Monoclonal Antibodies in Multiple Myeloma Come of Age. (2015) (24)
Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system (1999) (23)
Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia (2017) (23)
Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1 (2021) (23)
Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies (2016) (22)
Infection analysis in acute lymphoblastic leukemia: a report of 499 consecutive episodes in India. (1994) (22)
Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. (2015) (22)
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma (2018) (22)
Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma (2006) (22)
Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study) (2015) (22)
Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). (2021) (21)
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells (2006) (21)
Plasma Cell Tumors (2003) (21)
Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. (2021) (21)
A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma (2018) (21)
Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study (2008) (21)
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. (2021) (20)
BCL2 blockade overcomes MCL1 resistance in multiple myeloma (2019) (19)
Role of Decorin in Multiple Myeloma (MM) Bone Marrow Microenvironment (2013) (19)
Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study) (2015) (19)
VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). (2014) (19)
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial (2009) (19)
The rise of western medicine in India (1996) (18)
in patients with multiple myeloma Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels (2000) (18)
AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β (2008) (18)
Management of relapsed and relapsed/refractory multiple myeloma. (2011) (18)
Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM) (2014) (18)
Advances in supportive care for multiple myeloma. (2014) (18)
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma (2016) (17)
Introduction: the evolving role of bisphosphonate therapy in multiple myeloma. (2000) (17)
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America (2018) (17)
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. (2021) (17)
Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study (2020) (17)
Melanotic neuroectodermal tumor of infancy: Report of a case with ganglionic differentiation (1994) (17)
Bone Disease in Multiple Myeloma. (2016) (17)
Pim2 is important for regulating DNA damage response in multiple myeloma cells (2016) (17)
Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM) (2014) (17)
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. (2022) (17)
Targeting BRAF in multiple myeloma. (2013) (16)
Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study) (2016) (16)
In vivo and in vitro cytotoxicity of R‐etodolac with dexamethasone in glucocorticoid‐resistant multiple myeloma cells (2006) (16)
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA (2022) (16)
A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (2014) (15)
Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma) (2018) (15)
Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors (2014) (15)
ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study) (2015) (15)
Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma (2012) (15)
Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates. (2012) (14)
A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma (2019) (14)
Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). (2015) (14)
New monoclonal antibodies on the horizon in multiple myeloma (2017) (14)
Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease. (2017) (14)
Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis (2020) (14)
Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results. (2009) (14)
Future Novel Single Agent and Combination Therapies (2009) (13)
A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005) (2015) (13)
Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM) (2008) (13)
Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. (1996) (13)
selective HDAC 6 inhibitor , ACY-1215 , in combination with bortezomib in Preclinical activity , pharmacodynamic and pharmacokinetic properties of a (2012) (13)
Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma (2019) (13)
RGB 286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDKDependent and Independent Survival Mechanisms (2008) (13)
Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (Leukemia (2008) vol. 22 (1925-1932) 10.1038/leu.2008.174) (2008) (13)
Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states (2018) (13)
Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study (2015) (12)
Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. (2011) (12)
CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002 (2021) (12)
Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference (2017) (12)
Low incidence of CNS relapse with cranial radiotherapy and intrathecal methotrexate in acute lymphoblastic leukemia. (1996) (12)
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. (2016) (12)
Current management and emerging treatment strategies for multiple myeloma. (2019) (11)
Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma (2016) (11)
Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM) (2015) (11)
An International, Randomized, Double Blind Trial Comparing Denosumab With Zoledronic Acid (ZA) for the Treatment of Bone Disease in Patients (Pts) With Newly Diagnosed Multiple Myeloma (2017) (11)
Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma (2014) (11)
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma (2021) (11)
Introduction: the evolving role of bisphosphonate therapy in multiple myeloma (2000) (11)
Bisphosphonates and atypical femoral fractures. (2010) (11)
Case records of the Massachusetts General Hospital. Case 7-2010. A 49-year-old man with peripheral neuropathy and ascites. (2010) (11)
Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma (2015) (11)
Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM) (2014) (11)
Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis (2010) (11)
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study. (2009) (11)
How to Treat High-Risk Myeloma at Diagnosis and Relapse. (2021) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo. (2004) (10)
Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study (2018) (10)
Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials (2020) (10)
PI 3 K / p 110 is a novel therapeutic target in multiple myeloma (2010) (10)
Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma (2021) (10)
Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma (2020) (10)
Combination of the mTOR inhibitor Rapamycin and Revlimid ( CC-5013 ) has synergistic activity in Multiple Myeloma (2004) (10)
Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue. (1996) (10)
Management of Relapsed and Relapsed/Refractory Multiple Myeloma (2011) (10)
Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation. (2017) (10)
Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy. (2016) (9)
Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels in patients with multiple myeloma (2000) (9)
Clinical Grade “SNaPshot” Genetic Mutation Profiling in Multiple Myeloma (2014) (9)
Comprehensive Genetic Interrogation of Circulating Multiple Myeloma Cells at Single Cell Resolution (2016) (9)
Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (2015) (9)
High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial (2017) (9)
ATRAID regulates the action of nitrogen-containing bisphosphonates on bone (2020) (9)
A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. (2018) (9)
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* (2012) (9)
Treatment of Smoldering Multiple Myeloma: Ready for Prime Time? (2020) (9)
Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM) (2010) (9)
Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma. (1999) (9)
Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics (2019) (9)
Sodium fluoride PET imaging as a quantitative pharmacodynamic biomarker for bone homeostasis during anti-DKK1 therapy for multiple myeloma (2017) (9)
Restoration of Bone Balance Via Activin a Inhibition Results in Anti-Myeloma Activity (2008) (9)
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. (2014) (8)
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma (2021) (8)
Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications. (2006) (8)
Minimal residual disease in multiple myeloma: why, when, where. (2021) (8)
Clinical trials of bisphosphonates in multiple myeloma. (2012) (8)
Genetic predisposition for medication-related osteonecrosis of the jaws: a systematic review. (2019) (8)
Current Treatment Strategies for Multiple Myeloma. (2020) (8)
Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial. (2013) (7)
Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study. (2013) (7)
Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy (2020) (7)
Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis (2000) (7)
Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study (2019) (7)
Adult acute lymphoblastic leukemia: results of an aggressive regimen in India. (1994) (7)
Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM) (2017) (7)
CD 40 activation mediates p 53-dependent cell cycle regulation in human multiple myeloma cell lines (2000) (7)
Sequencing of nontransplant treatments in multiple myeloma patients with active disease. (2016) (7)
Monitoring protein synthesis in single live cancer cells. (2016) (7)
Inhibition of the TGF-β Signaling Pathway in Tumor Cells (2007) (6)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (2008) (6)
Case records of the Massachusetts General Hospital: Case 29-2011: A 66-year-old woman with cardiac and renal failure. (2011) (6)
An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma. (2009) (6)
Psychosocial effects of the relaxation response resiliency program (SMART-3RP) in patients with MGUS and smoldering multiple myeloma: A waitlist controlled randomized clinical trial. (2017) (6)
Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation towards Osteoblastic Lineage. (2006) (6)
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma (2022) (6)
Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma – a phase I/II feasibility and tolerance study of 17 patients (2000) (6)
Targeting Bcl-2 as Therapy for Multiple Myeloma. (2005) (6)
A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma (2019) (6)
Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study (2010) (5)
Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). (2022) (5)
Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA. (2019) (5)
The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma. (2006) (5)
A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. (2018) (5)
Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma (2011) (5)
MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). (2013) (5)
KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation (2022) (5)
A proto-oncogene BCL 6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells (2010) (5)
Carfilzomib (CFZ, Kyprolis®), lenalidomide (LEN, Revlimid®), and dexamethasone (DEX) (KRd) combined with autologous stem cell transplant (ASCT) shows improved efficacy compared with KRd without ASCT in newly diagnosed multiple myeloma (NDMM) (2015) (5)
Arachidonic Acid Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma (2018) (5)
Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease (2008) (5)
Multiple Myeloma - a New Era of Treatment Strategies (2012) (5)
Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. (2021) (5)
THE CARDIOVASCULAR EFFECTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS (2019) (5)
Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells. (2018) (5)
MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma. (2014) (5)
Combination of Nab-Rapamycin and Perifosine Induces Synergistic Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in Multiple Myeloma (MM) (2008) (4)
AZD6244 (ARRY-142886), a Potent and Selective MEK1/2 Inhibitor Blocks the ERK1/2 Signaling Pathway, Inhibits Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications. (2006) (4)
Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study (2016) (4)
Cell-free DNA for the detection of emerging treatment failure in relapsed/refractory multiple myeloma (2021) (4)
Inhibition of the TGF-beta signaling pathway in tumor cells. (2007) (4)
Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM). (2018) (4)
The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo (2008) (4)
Perspectives in the Rapidly Evolving Treatment Landscape of Multiple Myeloma: Expert Review of New Data Presentations from ASH 2019. (2020) (4)
Digital Health for Patients With Multiple Myeloma: An Unmet Need. (2021) (4)
Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study (2022) (4)
Multiple myeloma (1994) (4)
Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access. (2022) (4)
Practical considerations and role of Daratumumab retreatment for relapsed refractory Multiple Myeloma (2019) (4)
Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation (2021) (4)
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee (2022) (4)
Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease (2012) (4)
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma (2022) (4)
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. (2021) (4)
Lifestyle considerations in multiple myeloma (2021) (4)
Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma (2011) (4)
A phase II, single-arm study of denosumab in multiple myeloma patients with renal insufficiency. (2020) (4)
A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity (2013) (4)
The Treatment of Multiple Myeloma Patients Not Eligible for Asct (2010) (4)
PS1390 PRELIMINARY DATA: PHASE 1B STUDY OF FEASIBILITY/SAFETY OF ISATUXIMAB SHORT DURATION FIXED VOLUME INFUSION IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (2019) (4)
TEMPI: A Reversible Syndrome Following Treatment with Bortezomib (2012) (4)
Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide (2011) (4)
Mature Osteoblasts Provide a Protective Niche Against Multiple Myeloma Growth and Survival within the Tumor Microenvironment (2018) (4)
Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1. (2022) (4)
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma (2022) (4)
MM-096: Isatuximab Short-Duration Fixed-Volume Infusion Combination Therapy for Relapsed/Refractory Multiple Myeloma: Final Results of a Phase 1b Feasibility/Safety Study (2020) (4)
B Cell Lymphoma In Association with Multiple Myeloma: Analysis of the Biologic Relationship (2011) (4)
ATRAID, a genetic factor that regulates the clinical action of nitrogen-containing bisphosphonates on bone (2018) (3)
Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study (2019) (3)
Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma. (2011) (3)
A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma (2014) (3)
Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells (2010) (3)
Analysis of Hospitalization and Readmissions after CAR T Cell Therapy (2018) (3)
How We Approach Smoldering Multiple Myeloma (2020) (3)
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma (2006) (3)
Cancer Therapy : Preclinical The Monoclonal Antibody nBT 062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD 138-Positive Multiple Myeloma Cells In vitro and In vivo (2009) (3)
Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology (2019) (3)
OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa (2021) (3)
Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma (2011) (3)
Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma (2013) (3)
Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma (2021) (3)
Polyunsaturated Fatty Acid (PUFA) Signaling Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma (2019) (3)
Cancer Therapy : Preclinical In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN 9708 against Multiple Myeloma Cells (2011) (3)
CAL-101, a Specific Inhibitor of the p110δ Isoform of Phosphatidylinositide 3-Kinase Induces Cytotoxicity in Multiple Myeloma (MM) (2008) (3)
KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) (2021) (2)
A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma (2009) (2)
PF592 IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA (2019) (2)
Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma (2019) (2)
Patient Preferences for Multiple Myeloma (MM) Treatment: Interim Analysis of a Discrete Choice Experiment (2018) (2)
Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study. (2010) (2)
Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma (2022) (2)
B483 A Novel Small-Molecule Inhibitor RGB 286638 Induces Apoptosis and Necrosis in Multiple Myeloma (2009) (2)
Bortezomib induces canonical nuclear factor- (cid:1) B activation in multiple myeloma cells (2009) (2)
Case 29-2011 (2011) (2)
Lenalidomide In Combination with the Activin Receptor Type II Murine Fc Protein RAP-011: Preclinical Rationale for a Novel Anti-Myeloma Strategy (2010) (2)
Pleiotropic activity of the novel cyclin-dependent kinase inhibitor RGB 286638 predicts therapeutic potential in multiple myeloma (2008) (2)
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (2)
JS-K, a GST-Activated Nitric Oxide Generator, Induces DNA-Double Strand Breaks and Inhibits Growth and Survival of Multiple Myeloma Cells In Vitro and In Vivo. (2006) (2)
COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia (2021) (2)
AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity (2010) (2)
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone (wKRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM) (2019) (2)
AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition. (2009) (2)
Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma. Reply. (2019) (2)
Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma. (2007) (2)
Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma (2021) (2)
Treatment Patterns among Patients with Recently-Diagnosed Multiple Myeloma in a National Registry (2008) (2)
Ethical challenges with multiple myeloma BCMA CAR-T slot allocation: a multi-institution experience. (2023) (2)
Early Mortality in Newly Diagnosed Multiple Myeloma in the Context of Novel Drugs (2015) (2)
P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (2022) (2)
MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM) (2021) (2)
Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma (2014) (2)
Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma. (2010) (2)
HDAC Inhibition in Multiple Myeloma with a Focus on Selective HDAC6 Inhibition (2015) (2)
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo. (2008) (2)
Response with combined modality treatment in childhood rhabdomyosarcoma (1993) (2)
The Pleiotropic Immunosuppressive Role of Osteoclasts in Multiple Myeloma (2018) (2)
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma (2000) (2)
Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival (2022) (2)
Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). (2014) (2)
Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial (2011) (2)
Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM). (2015) (2)
B203 A New Anti-Dkk-1 Antibody Targeting Myeloma Bone Disease (2009) (2)
Multiple Myeloma Cells Induce Lipolysis in Adipocytes and Uptake Fatty Acids through Fatty Acid Transporter Proteins (2020) (2)
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. (2022) (1)
A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (2020) (1)
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose (2021) (1)
P-151: Incidence of adverse events in patients with Multiple Myeloma who continued with Denosumab after receiving Denosumab or Zoledronic acid: an open-label extension study (2021) (1)
OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM) (2021) (1)
A349 Phase I/II Trial of Perifosine + Bortezomib in Rel/Ref MM Patients Previously Treated with Bortezomib (2009) (1)
The monoclonal antibody nBT 062 conjugated to maytansinoids has potent and selective cytotoxicity against CD 138 positive multiple myeloma cells in vitro and in vivo (2008) (1)
Clinical, Radiographic, and Biomarker Characterization of Multiple Myeloma Patients with Bisphosphonate Associated Osteonecrosis of the Jaw. (2006) (1)
Molecular Profiling of Extramedullary and Medullary Plasmacytomas. (2008) (1)
Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma (2016) (1)
Serotonin Receptor Antagonists Have an In Vitro and In Vivo Anti-Myeloma Effect That Is Mainly Mediated by Caspase Dependent Apoptosis. (2006) (1)
The effect of selective inhibition of HDAC6 with ACY1215 on bortezomib activity in multiple myeloma (MM). (2011) (1)
R-Etodolac and a Novel Indole-Pyran Structural Analog, SDX-308, Induce Cytotoxicity and Overcome Drug Resistance in Multiple Myeloma. (2005) (1)
Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment (2012) (1)
B037 CAL-101: A Selective Inhibitor of PI3K p110D for the Treatment of Multiple Myeloma (2009) (1)
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41) (2021) (1)
Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma (2022) (1)
Best of 2017 in Multiple Myeloma (2018) (1)
798 Prognostic factors in multiple myeloma (1995) (1)
799 VAMP/C-VAMP infusional chemotherapy as induction treatment for previously untreated multiple myeloma (1995) (1)
246 Comparison of two stem cell mobilization and harvesting regimens for peripheral blood stem cell (PBSC) transplantation in multiple myeloma (MM) (1995) (1)
Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease. (2007) (1)
Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma (2019) (1)
Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma (2016) (1)
Inhibition Of Myeloid Derived Suppressor Cells (MDSC) In The Multiple Myeloma Bone Marrow Microenvironment (2013) (1)
Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study. (2018) (1)
A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma. (2015) (1)
Continuous lenalidomide (LEN) therapy versus observation following nonimmunomodulatory compound-based induction therapy in newly diagnosed multiple myeloma (NDMM): MM-027 trial. (2014) (1)
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study (2022) (1)
Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052. (2005) (1)
Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00. (2006) (1)
Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients. (2021) (1)
New Clinical and Research Directions in Myeloma-Related Bone Disease (2015) (1)
JS-K, a GST-Activated Nitric Oxide Generator, Induces Apoptosis and Overcomes In Vitro Drug Resistance in Multiple Myeloma Cells. (2005) (1)
Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study. (2017) (1)
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy (2000) (1)
Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia (2022) (1)
Bone Disease in Multiple Myeloma: Biologic and Clinical Implications (2022) (1)
DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma (2011) (1)
Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma (2022) (1)
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study (2022) (1)
Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma. (2021) (1)
BONE MARROW ADIPOSE TISSUE VOLUME INDEPENDENTLY ASSOCIATES WITH ATHEROSCLEROTIC DISEASE BURDEN AND MACE (2020) (1)
Abstract 2530: Antimyeloma activity of a small molecule multi-targeted kinase inhibitor, AT9283, via potent aurora kinase and STAT3 inhibition (2010) (1)
Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM (2020) (1)
The In Vivo Activity of Neutralizing B Cell-Activating Factor (BAFF) Antibody in the Treatment of Multiple Myeloma (MM). (2006) (1)
Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma (2021) (1)
Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma. (2004) (1)
Clinical grade SNaPshot genetic mutation profiling in multiple myeloma. (2014) (1)
Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma (2012) (1)
Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease (2012) (1)
A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma. (2014) (1)
The research mission in myeloma (2009) (1)
Updates to the NCCN Guidelines (2013) (1)
Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM). (2009) (1)
Endothelial Cells Induce Multiple Myeloma Cell Proliferation Protect Against Conventional and Novel Therapies. (2004) (1)
MLN 120 B , a Novel I K BKinase B Inhibitor , Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (1)
Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations (2009) (1)
Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma (2018) (1)
Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study (2021) (1)
Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma (2022) (1)
Advances in Brief Functional Interaction between Retinoblastoma Protein and Stress-activated Protein Kinase in Multiple Myeloma Cells 1 (1999) (1)
CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies (2010) (1)
New Treatments for Optimizing Bone Health in Patients With Multiple Myeloma: Proceedings From the Symposium Held at the IX International Meeting on Cancer-Induced Bone Disease (2010) (1)
Novel In Vivo Model of Multiple Myeloma Bone Disease Using ß-Tricalcium Phosphate Artificial Bone Grafts (2015) (1)
The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma (2013) (1)
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial) (2022) (1)
Giving voice to patients: Understanding treatment preferences of patients with multiple myeloma (MM). (2019) (1)
The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM). (2005) (1)
Is Upfront Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma the Standard (2017) (1)
620O CART-ddBCMA for multiple myeloma: Interim results from phase I study (2022) (1)
Osteoclast Activation in Multiple Myeloma (2010) (1)
Denosumab Compared with Zoledronic Acid for Preventing Skeletal Complications in Patients with Multiple Myeloma: A Randomized, Phase 3, Double-Blind, Double-Dummy Trial (2012) (1)
Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study. (2021) (1)
Denosumab compared with zoledronic acid for the treatment of bone disease in adults with newly diagnosed multiple myeloma: An international, randomized, double-blind trial. (2015) (1)
Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study (2019) (1)
Do We Need Another HDAC Inhibitor in Multiple Myeloma (2015) (1)
Twice-weekly Ixazomib plus Lenalidomide-dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-term Follow-up Data for Patients Not Undergoing Stem Cell Transplantation (SCT) (2017) (1)
Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib (2008) (1)
1 JSK , a GST-activated nitric oxide generator , induces DNA double strand breaks , activates DNA damage response pathways , and induces apoptosis in vitro and in vivo in human multiple myeloma cells (2007) (1)
Effect of the specific P53 stabilizer CBS9106 on multiple myeloma (MM). (2016) (1)
Bortezomib Targets Multiple Myeloma Endothelial Cells. (2004) (1)
Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network (2022) (1)
Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma (2010) (1)
Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis (2011) (1)
Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM) (2018) (0)
apoptosis myeloma by induction of caspase-dependent and -independent Honokiol overcomes conventional drug resistance in human multiple (2010) (0)
Minimal resid ual dis ease in mul ti ple mye loma : why , when , where (2021) (0)
P968: ADDITION OF IXAZOMIB TO POMALIDOMIDE AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS PROGRESSING ON LENALIDOMIDE AS PART OF 1ST LINE THERAPY: ALLIANCE A061202 (2022) (0)
Case 27-2001: Waldenstrom's macroglobulinemia. (2002) (0)
Overcoming MCL1 Resistance in Multiple Myeloma (2018) (0)
[4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth In vitro and in vivo activity of atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro (2005) (0)
Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA (2021) (0)
Infectious Complications in Patients Following B-Cell Maturation Antigen: Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (2023) (0)
Title: Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients (2013) (0)
SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma. (2004) (0)
Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment. (2004) (0)
Targeting Src-family kinase activation and downstream molecular events to overcome MM cell growth, survival, and drug-resistance. (2005) (0)
The Role of Novel Therapies in Myeloma Patients with Renal Insufficiency (2012) (0)
Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma (2019) (0)
The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy (2015) (0)
Cancer Therapy: Preclinical In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells (2011) (0)
Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers (2016) (0)
A CASE OF VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE, CHRONIC LUNG DISEASE, AND RECURRENT INFECTIONS (2018) (0)
specific cytotoxic T lymphocytes - Ex vivo induction of multiple myeloma (2013) (0)
Genetic Predisposition for Medication-Related Osteonecrosis of the Jaws: A Systematic Review (2019) (0)
Inhibition of fatty acid synthase induces anti-tumor effect in multiple myeloma (2008) (0)
Bone Marrow Adipocytes Induce Metabolic Reprogramming of Multiple Myeloma Cells (2021) (0)
OAB-029: Bone marrow adipocytes induce metabolic reprogramming of multiple myeloma cells (2021) (0)
PreclinicalActivityoftheOralProteasomeInhibitorMLN9708 in Myeloma Bone Disease (2014) (0)
Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma. (2009) (0)
Anemia and Erythropoeitic Growth Factors in Multiple Myeloma (2008) (0)
Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation. (2007) (0)
The Role of the Bone Marrow Microenvironment in the Pathogenesis of Multiple Myeloma (2007) (0)
Use of Alkylating Agents Among Patients with Multiple Myeloma in a National Registry, 2006-2008. (2009) (0)
Induction of Apoptosis by Didox Via Down-Regulation of Bcl-2 Family Proteins in Multiple Myeloma (MM). (2004) (0)
Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma (2021) (0)
Erratum (2006) (0)
PF612 ONCE-WEEKLY (70 MG/M2) VERSUS TWICE-WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (2019) (0)
Novel Bone-Targeting Agents in Multiple Myeloma (2009) (0)
Epigenetic modulation by VidazaTM induces apoptosis and overcomes in vitro drug resistance in human multiple myeloma cells. (2007) (0)
Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy (2023) (0)
Evolving therapies for multiple myeloma (2011) (0)
OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study (2021) (0)
Other Plasma Cell Dyscrasias (2003) (0)
Leaving Lytic Lesions-Is There New Role for Radiation in Multiple Myeloma in the CAR T Era? (2022) (0)
Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells. (2018) (0)
Determining Resistance Mechanisms in BRAF-mutated Multiple Myeloma (2019) (0)
VEGF Upregulates Mcl-1 Expression and Protects Multiple Myeloma Cells Against Starvation Induced-Apoptosis. (2004) (0)
CCR1 Inhibition Targets Osteoclast-Myeloma Adhesion and Exerts in Vivo Anti-Osteoclast Activity (2008) (0)
Peripheral Blood Genomic Interrogation in Myeloma: Developing a Blood Biopsy to Replace the Bone Marrow Biopsy (2017) (0)
Overcoming p53 Loss with a Multi-Targeted Small Molecule Inhibitor in Multiple Myeloma. (2009) (0)
IN THE SPOTLIGHT Targeting BRAF in Multiple Myeloma (2013) (0)
Role of Salvage Autologous Transplant in Multiple Myeloma (2016) (0)
797 Single centre results of therapy including autografts in previously untreated myeloma (1995) (0)
P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3 (2022) (0)
Multiple myeloma (2001) (0)
MicroRNA expression patterns in medullary and extramedullary plasmacytoma (2014) (0)
MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM) (2021) (0)
Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting (2018) (0)
Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma (2010) (0)
cells in the multiple myeloma microenvironment in humans Tumor-promoting immune-suppressive myeloid-derived suppressor (2013) (0)
AUTOINFLAMMATORY DISORDER IN A PEDIATRIC PATIENT (2018) (0)
Combining PD-1 Inhibition With Pemalidomide for Relapsed/Refractory Multiple Myeloma (2017) (0)
Epigenetic Modulation by Vidaza™ induces Apoptosis and Overcomes In Vitro Drug Resistance in Human Multiple Myeloma Cells. (2006) (0)
New Developments in Multiple Myeloma (2014) (0)
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial (2021) (0)
Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs (2008) (0)
Cancer Therapy : Preclinical Preclinical Activity of theOral Proteasome InhibitorMLN 9708 in Myeloma Bone Disease (2014) (0)
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop. (2023) (0)
Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications. (2007) (0)
P-042: Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (2022) (0)
Pomalidomide for the treatment of relapsed and refractory multiple myeloma (2014) (0)
Current & Emerging Therapeutics for Multiple Myeloma (2013) (0)
Defining the differentiation states of multiple myeloma at single cell resolution – Identifying opportunities for immunotherapy (2019) (0)
Panobinostat and Multiple Myeloma in 2018 The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters (2018) (0)
Comparison of Denosumab Versus Intravenous (IV) Bisphosphonate Use for Hypercalcemia in Multiple Myeloma (2020) (0)
Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells. (2006) (0)
Targeting Glycolysis and Compensatory Mitochondrial Metabolism In An In Vivo Xenograft Model Of Multiple Myeloma With FDA Approved Ritonavir and Metformin (2013) (0)
P-150: Quality of life, psychological distress, and prognostic awareness in patients with Multiple Myeloma (2021) (0)
P209 Hypereosinophilic syndrome presenting as acute necrotizing eosinophilic myocarditis: a case of rapid improvement with corticosteroids (2016) (0)
Upregulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma and other malignancies (2007) (0)
P-065: CyTOF and single cell RNA sequencing reveal altered T cell phenotypes in Multiple Myeloma patients: implications for immunotherapy (2021) (0)
Abstract 14967: Cardiac Toxicity and Cardiovascular Events Among Adult Patients Treated With Chimeric Antigen Receptor T-Cells: A Multi-Center Registry (2019) (0)
Assessment of Knowledge and Performance Gaps in the Treatment of Patients with Multiple Myeloma (2010) (0)
Perceptions of prognosis in caregivers of multiple myeloma (MM) patients. (2021) (0)
B469 Unraveling the Synergism of Nab-Rapamycin and Perifosine Combination in Multiple Myeloma (2009) (0)
Multiple myeloma. (2000) (0)
Upregulation of c-Jun Induces Cell Death Via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma. (2006) (0)
Novel Drugs Push the Envelope in Multiple Myeloma (2016) (0)
BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma. (2006) (0)
In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM). (2004) (0)
Attitudes toward Participation in Research, New Treatments, and Medication Side Effects among Multiple Myeloma and Myelodysplastic Syndrome Patients - The Patient Registries at Slone: Myeloma & MDS. (2007) (0)
P192 Recurrent HSV-1 infection in an infant secondary to a TLR-3 defect (2016) (0)
P-107: NCOR2 mediated MYC upregulation drives drug resistance in multiple myeloma independent of Cereblon (2021) (0)
Treatment Strategy for Relapse and Refractory Multiple Myeloma and Role of Pomalidomide (2019) (0)
OAB-007: Updated clinical and correlative results from the Phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and/or refractory multiple myeloma (2022) (0)
Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy (2022) (0)
RECURRENT AND CYCLIC FEVERS IN A PEDIATRIC PATIENT (2018) (0)
synergistic activity in multiple myeloma Combination of the mTOR inhibitor rapamycin and CC-5013 has (2013) (0)
B457 AT7519, a Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma via GSK3B (2009) (0)
Reply to the Letter to the Editor from Noopur Raje and Kenneth C. Anderson (2008) (0)
multiple myeloma cell lines CD40 activation mediates p53-dependent cell cycle regulation in human (2008) (0)
Molecular Features and Clinical Outcomes of Extramedullary Plasmacytomas (2021) (0)
OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (2022) (0)
Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma (2010) (0)
Updates and rationale of clinical trials in multiple myeloma (2019) (0)
Role of Osteoblast in Myeloma Pathology (2013) (0)
New immune modulators (2013) (0)
Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors. (2004) (0)
Detection of Kaposi's Sarcoma Herpesvirus Gene Sequences Multiple Myeloma Are Phenotypically and Functionally Normal Despite the Bone Marrow and Peripheral Blood Dendritic Cells From Patients With (2008) (0)
CCL3 Impairs Osteoblast Function Via Downregulation of Osteocalcin. (2009) (0)
Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma (2014) (0)
Role of Sclerostin in Multiple Myeloma Progression (2017) (0)
Diagnostic Advances in Multiple Myeloma: The Role of Magnetic Resonance Imaging (2015) (0)
Chimeric Antigen Receptor T Cells for the Treatment of Multiple Myeloma (2016) (0)
Transitioning to an All Oral Therapy for Multiple Myeloma with the Novel Proteasome Inhibitor Ixazomib (2015) (0)
Carbon-11-Labelled Methionine PET/CT in Patients With FDG-Occult Multiple Myeloma: A Prospective Pilot Study. (2022) (0)
Checking Multiple Myeloma with Pembrolizumab (2016) (0)
Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy (2012) (0)
Where is the “Attention Deficit” in ADHD? Perspectives from Cognitive Neuroscience and Recommendations for Future Research (2007) (0)
against apoptosis VEGF induces MCL-1 upregulation and protects multiple myeloma cells (2013) (0)
Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma (2011) (0)
Once-weekly (70 mg/m2) versus twice-weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM). (2019) (0)
801 Second autografts for relapsed myeloma (1995) (0)
The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development (2011) (0)
High dose of Zoledronic acid inhibits both osteoclasts and osteoblasts in an In Vivo mouse model (2008) (0)
Mature Osteoblasts Are Critical Bone Marrow Niche Cells Regulating Multiple Myeloma Cell Growth, at Least in Part, By Affecting the Local Immune Microenvironment (2021) (0)
The Etiology and Pathophysiology of Multiple Myeloma (2010) (0)
Monoclonal Antibodies in the Treatment of Multiple Myeloma with a Focus on Elotuzumab and Daratumumab (2015) (0)
Multiple myeloma gammopathies BCL 2 blockade overcomes MCL 1 resistance in multiple myeloma (2019) (0)
B281 Ciliary Proteins and Hedgehog Pathway in Multiple Myeloma (2009) (0)
B357 Targeting Myeloma Bone Disease via Activin A Inhibition (2009) (0)
Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues. (2004) (0)
Combining Daratumumab With Backbone Antimyeloma Agents (2016) (0)
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (2021) (0)
Evaluating efficiency of bone marrow harvest and its manipulation--role of CD 34 positivity. (1995) (0)
Didox Induced Apoptosis Occurs by Inhibiting DNA Synthesis and Repair Via Down-Regulation of Ribonucleotide Reductase M1 in Multiple Myeloma (MM). (2005) (0)
M287 AN ATYPICAL PRESENTATION OF STAT3 HYPER-IGE SYNDROME (2019) (0)
A Novel in-Vivo Model to Examine Homing of Multiple Myeloma Cells in Postnatal, Inducible, and Reversible Loss of Mature Osteoblasts (2020) (0)
From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma (2009) (0)
17 – Multiple Myeloma and Plasma Cell Dyscrasias (2010) (0)
NCOR2 Mutations Are Associated with IMiD Resistance in Human Myeloma Cells (2020) (0)
MRD Detection Testing to Study Clonal Selection and Drug Resistance (2016) (0)
Mature Osteoblasts Promote Multiple Myeloma Survival through Cell-Cell Contact and Immune Modulation Mechanisms (2019) (0)
the Use of Tailored Feedback to Improve Hematologist Competence and Clinical Decision Making for the Treatment of Patients with Multiple Myeloma: a Novel Web-Based Educational Solution (2016) (0)
p38MAPK Inhibitor LSN2322600 Modulates the Bone Marrow Microenvironment and Inhibits Osteoclastogenesis in Multiple Myeloma. (2006) (0)
My COVID-19 experience (2020) (0)
The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells. (2004) (0)
The TEMPI Syndrome: Telangiectasias, Elevated Erythropoietin and Erythrocytosis, Monoclonal Gammopathy, Perinephric Fluid Collections, and Intrapulmonary Shunting (2011) (0)
Myeloma Bone Marrow Stromal Cells Detection of Kaposi's Sarcoma Herpesvirus DNA Sequences in Multiple (2013) (0)
Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment. (2005) (0)
Hypogammaglobulinemia and Risk of Infectious Complications in Patients Receiving Idecabtagene vicleucel (2023) (0)
Table 136-3, Classification of Monoclonal Gammopathies (2003) (0)
Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis (2022) (0)
Increased Sensitivity to DNA Damage Multiple Myeloma Cells Is Associated with Ku86 Variant Expression and Function in (2013) (0)
P-134: Quality of life, psychological distress, and prognostic awareness in caregivers of patients with Multiple Myeloma (2021) (0)
NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells. (2009) (0)
P-282: Addition of ixazomib to pomalidomide-dexamethasone improves progression-free survival for myeloma patients progressing on frontline lenalidomide: results of the randomized alliance study A061202 (2022) (0)
OAB-012: Early and sustained negative minimal residual disease (MRDneg) after idecabtagene vicleucel (ide-cel) defines a subset of multiple myeloma (MM) patients in KarMMa achieving prolonged survival (2022) (0)
Effect of the Wnt-Signaling Inhibitor Sclerostin and Bone Marrow Adipocytes on Multiple Myeloma (2016) (0)
MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation. (2006) (0)
Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma (2012) (0)
Practice-Changing Daratumumab Combinations for the Treatment of Multiple Myeloma (2017) (0)
Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy (2019) (0)
Bcl-2, Mcl-1 and p53 Expression Confer Sensitivity to Bcl-2 Inhibitor ABT-737 in Multiple Myeloma. (2006) (0)
Treatment of Patients in First or Second Relapse (2018) (0)
myeloma interaction of tumor and bone marrow accessory cells in multiple Immunomodulatory effects of lenalidomide and pomalidomide on (2012) (0)
Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/β-Catenin Pathway. (2006) (0)
MLN120B, a Novel IKBKinase B Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (0)
Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma (2021) (0)
814 Peripheral blood transplants followed by maintenance interferon in myeloma (1995) (0)
Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma. (2007) (0)
Analysis of Healthcare Professional Management of CAR T-Cell Toxicities and Concordance with Expert Consensus Recommendations (2022) (0)
OAB-003: Phase 1 study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain for the treatment of subjects with relapsed and refractory multiple myeloma (2022) (0)
Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma (2012) (0)
Extending Dosing Intervals of Denosumab As a Maintenance Strategy in Multiple Myeloma: A Real-World Experience at a Large Academic Cancer Center (2020) (0)
The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG) (2019) (0)
Rhabdomyosarcoma in children :clinical features and results of an aggressive chemotherapy regimen. (1996) (0)
Inhibition of Hsp90 Targets Multiple Myeloma Cell Growth, Angiogenesis, and Osteoclastogenesis in the BM Microenvironment. (2007) (0)
Small Molecule Therapeutics Delineating themTORKinasePathwayUsingaDual TORC 1 / 2 Inhibitor , AZD 8055 , in Multiple Myeloma (2014) (0)
Dietary Supplement Vitamin C Significantly Abrogates Bortezomib-Induced Multiple Myeloma (MM) Cell Growth Inhibition (2008) (0)
by Dexamethasone Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced (2013) (0)
Circulating tumor DNA in the peripheral blood as early predictor of clinical outcome in relapsed/ refractory multiple myeloma (2019) (0)
Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells. (2006) (0)
P270 An expanding spectrum of autoinflammatory syndromes: TNFAIP3-related disease (2017) (0)
In Vivo Effects of Zoledronic Acid on Bone Remodeling. (2007) (0)
AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma (2012) (0)
CYC202 (seliciclib or R-Roscovitine), a small molecule cyclin dependent kinase inhibitor, overcomes drug resistance via down-regulation of Mcl-1 in multiple myeloma (MM) (2005) (0)
Programming Myeloma Cell Death With Venetoclax (2017) (0)
OAB-045: COVID-19 vaccine responsiveness in patients with Multiple Myeloma and Waldenström Macroglobulinemia (2021) (0)
1553TiPCOMPARISON OF DENOSUMAB VS ZOLEDRONIC ACID FOR TREATMENT OF BONE DISEASE IN ADULTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A RANDOMIZED, DOUBLE-BLIND, MULTINATIONAL PHASE 3 TRIAL. (2014) (0)
Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma. (2007) (0)
A227 Lenalidomide, Bortezomib, and Dexamethasone Is Active in High-Risk Relapsed/Refractory Myeloma (2009) (0)
P-002: Real-world observations and practical considerations of subcutaneous daratumumab administration in multiple myeloma (2021) (0)
CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells. (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Noopur S. Raje?

Noopur S. Raje is affiliated with the following schools:

Vrije Universiteit Amsterdam
University of Michigan
Fukuoka University
University of Turin
University of Salamanca
Massachusetts General Hospital

Noopur S. Raje's Academic­Influence.com Rankings

Noopur S. Raje's Degrees

Why Is Noopur S. Raje Influential?

Noopur S. Raje's Published Works

Published Works

What Schools Are Affiliated With Noopur S. Raje?

Noopur S. Raje's AcademicInfluence.com Rankings